Rebate Proposals Targeting Single-Use Vials May Be Barking Up The Wrong Tree
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
You may also be interested in...
There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.
Medicare Part B spending on discarded, weight-based drugs sold in single-use vials is around $725m annually. The National Academies of Science, Engineering and Medicine is evaluating strategies to reduce the waste.
Government price negotiations, financial transparency in the drug supply chain and changes to orphan drug incentives would go a long way toward making drugs more affordable, a National Academies committee says in a new report; dissent authored by two pharma industry veterans warns of 'unintended consequences' if recommendations are implemented.